One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Neuphoria Therapeutics Inc.
NEUP · NGM · Healthcare · Biotechnology
Current price
$2.69
52-week range
$2.62 - $5.53
Market cap
$14.56M
Balance sheet
Healthy
-639.68x Concerning
Net cash $19.83M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics develops medicines for brain conditions, like post-traumatic stress disorder and Alzheimer's, primarily earning money through collaborations and licensing deals with larger pharmaceutical companies. This approach means their success hinges on these partnerships and the progress of their experimental drugs through testing, which is important because it's how they fund their research and development.
How the company got here
Neuphoria Therapeutics Inc., originally known as Bionomics Limited, was founded in 1996. The company has focused on developing treatments for serious central nervous system (CNS) disorders. A key turning point was its name change to Neuphoria Therapeutics Inc. in December 2024, signaling a renewed focus or direction. The company is based in Millis, Massachusetts, and operates in Australia for its clinical development.
What it actually does
Neuphoria Therapeutics is a biopharmaceutical company in the clinical stage, meaning its drug candidates are being tested in human trials. They are developing new medicines that target specific proteins in the brain called ion channels. These channels play a crucial role in how nerve cells communicate. By modulating these channels, Neuphoria aims to treat complex neurological and psychiatric conditions that currently have limited treatment options.
BNC210 for Post-Traumatic Stress Disorder (PTSD)
Neuphoria's main focus is a drug candidate called BNC210, which is designed to treat post-traumatic stress disorder (PTSD). BNC210 works by being a selective negative allosteric modulator (a substance that reduces the activity of a target protein) of a specific receptor in the brain called the alpha7 nicotinic acetylcholine receptor. This is one of Neuphoria's distinct business lines, aiming to address a significant unmet medical need in mental health. The company is advancing this candidate through clinical trials to demonstrate its safety and effectiveness.
Alpha7 Positive Allosteric Modulators (pAMs) for Alzheimer's Disease
Another area of Neuphoria's research involves developing positive allosteric modulators (pAMs) for the same alpha7 receptor. These pAMs are intended to treat cognitive dysfunction, a common symptom in diseases like Alzheimer's. Neuphoria has a research collaboration and license agreement with Merck & Co., Inc. for this specific area. This partnership allows them to leverage expertise and resources to develop potential treatments for debilitating cognitive disorders, representing another key segment of their development pipeline.
What management is betting on now
Management's primary strategic focus is advancing their lead drug candidate, BNC210, through the necessary clinical trials to seek approval for treating PTSD. They are also actively pursuing the development of alpha7 positive allosteric modulators, particularly for cognitive impairments associated with Alzheimer's disease, through their collaboration with Merck. These efforts are crucial for the company's future as they aim to bring novel therapies to patients suffering from severe central nervous system disorders and to create value for the company.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
$1.17M
Net income
$-4.90M
Diluted EPS
2.21
Operating cash flow
$1.21M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-505.06K
Diluted EPS
-0.09
Operating cash flow
$-3.34M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$1.86M
Diluted EPS
-0.77
Operating cash flow
$-6.44M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-9.91M
Diluted EPS
-4.41
Operating cash flow
$-3.79M
Free cash flow
—
Fetching…
Sources
Revenue
$15.65M
Net income
$-400.00K
Diluted EPS
-5.55
Operating cash flow
$-3.59M
Free cash flow
—
Fetching…
Sources
Revenue
$15.00M
Net income
$11.26M
Diluted EPS
6.55
Operating cash flow
$11.45M
Free cash flow
—
Fetching…
Sources
Revenue
$662.72K
Net income
$-1.94M
Diluted EPS
-1.23
Operating cash flow
$-3.36M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-804.79K
Diluted EPS
0.00
Operating cash flow
$-4.43M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $2.69
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $19.8M - more cash than debt. Interest coverage -639.7x.
Net debt
$-19.83M
Interest coverage
-639.68x
Neuphoria Therapeutics Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
NEUP
BASELINE
Neuphoria Therapeutics Inc.
Total debt $34.34K Interest coverage -639.68x This is the baseline the peer rows are being compared against.
Total debt $609.87K Interest coverage -76.56x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -632.78x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -54.83x Neither company has much profit cushion over interest right now.
Total debt $28.74M Interest coverage -61.11x Neither company has much profit cushion over interest right now.
What you should know
The case for and against NEUP
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -61.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.09x
P/B
0.59x
P/S
12.40x
EV/EBITDA
0.63x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-15.7%
Net margin
0.0%
ROE
-61.7%
ROA
-19.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
27.85x
Quick ratio
27.33x
Total debt
$34.34K
Total cash
$19.87M
Growth
How the business has been compounding
Revenue TTM
$32.49M
Revenue 5Y CAGR
-92.5%
EPS TTM
-3.06
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-12.35M
Free CF TTM
$-12.35M
FCF margin
-38.0%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—